Denali Therapeutics Inc (DNLI)’s Pretax Margin and Net Margin Explained

Kevin Freeman

Denali Therapeutics Inc [DNLI] stock is trading at $20.25, down -3.25%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The DNLI shares have gain 7.83% over the last week, with a monthly amount glided 15.91%, and seem to be holding up well over a long-time horizon.

From an analyst’s perspective:

Previously, Cantor Fitzgerald upgraded its rating to Overweight on April 10, 2025. Deutsche Bank started tracking the stock assigning a Buy rating and suggested a price target of $31 on February 11, 2025. Robert W. Baird initiated its recommendation with a Outperform and recommended $31 as its price target on January 07, 2025. In a note dated December 16, 2024, Stifel upgraded an Buy rating on this stock but restated the target price of $37.

Denali Therapeutics Inc [DNLI] stock has fluctuated between $10.57 and $24.34 over the past year. Currently, Wall Street analysts expect the stock to reach $33 within the next 12 months. Denali Therapeutics Inc [NASDAQ: DNLI] shares were valued at $20.25 at the most recent close of the market. An investor can expect a potential return of 62.96% based on the average DNLI price forecast.

Analyzing the DNLI fundamentals

To continue investigating profitability, this company’s Return on Assets is posted at -0.47, Equity is -0.46 and Total Capital is -0.57. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.05.

Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.

Ratios To Look Out For

For context, Denali Therapeutics Inc’s Current Ratio is 9.79. As well, the Quick Ratio is 9.79, while the Cash Ratio is 1.01.

Transactions by insiders

Recent insider trading involved Watts Ryan J., President and CEO, that happened on Jan 06 ’26 when 35198.0 shares were sold. COFO and Secretary, Schuth Alexander O. completed a deal on Jan 06 ’26 to sell 17218.0 shares. Meanwhile, Consultant Ho Carole bought 17218.0 shares on Jan 06 ’26.

MZP News
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.